OBJECTIVE:To find out a new purifying process of Vernonia Anthelmintica Willd by clarifying agent.METHO-DS:Using orthogonal design L16(45),influcing factors including clarifing agent on extraction process were investigated by detecting the content of total flavone ingredients.RESULTS:Different ratios of concentration volume had significant influence on the content of total flavone ingredients(P

OBJECTIVE:To observe the superiority of countercurrent chromatography(CCC)in isolating active componets of botanicals.METHODS:By pharmacodynamic test,active components of herbs,isolated by CCC,were screened.RESULTS:An active part of herb was found and a component with a purity of95%was obtained.CONCLUSION:CCC is a rapid,effective and unabsorpting isolation technology compared with other methods in developing herbal researches.

OBJECTIVE:To investigate the effects of extracts of different constitutes of Vernonia Anthelmintica Willd different on the serum levels of Cu and Zn in mice METHODS:Different groups of mice were given separately with (B) 1/10,(C)1/30,(C′)1/50 doses of LD50 of extracts of different constitutes of Vernonia Anthelmintica Willd for 7 days,and the levels of Cu and Zn in serum were determined RESULTS:The levels of Cu and Zn in serum were different in different groups of mice(P

Objective:To analyze the situation of therapeutic drug monitoring ( TDM) for 3 new antiepileptic drugs including leve-tiracetam, lamotrigine and oxcarbazepine in our hospital to provide reference for the individualized drug treatment for the children with epilepsy. Methods:The basic information, dose and TDM data of levetiracetam, lamotrigine and oxcarbazepine of the children with ep-ilepsy during 2015 and 2016 were collected and statistically analyzed in our hospital. Results: Without obvious difference in mean dose, the average plasma concentrations of oxcarbazepine in 3-6-year-old,6-10-year-old and 10-18-year-old children were significantly higher than those in less than 3-year-old children(P<0. 05). The mean dose and the average plasma concentrations of lamotrigine in children at different ages had no statistical significance(P>0. 05). The average plasma concentration of levetiracetam in less than 3-year-old children was significantly higher than that in the other children (P<0. 05). The effective rate of clinical treatment within dif-ferent plasma concentration ranges had statistical significance(P<0. 05). Conclusion: There are inter-individual differences in the plasma concentrations of antiepileptic drugs among the children with epilepsy at different ages. So the plasma concentration of antiepi-leptic drugs should be monitored regularly in order to ensure the safety and effectiveness of medication for children.

Objective:To analyze the situation of therapeutic drug monitoring ( TDM) for 3 new antiepileptic drugs including leve-tiracetam, lamotrigine and oxcarbazepine in our hospital to provide reference for the individualized drug treatment for the children with epilepsy. Methods:The basic information, dose and TDM data of levetiracetam, lamotrigine and oxcarbazepine of the children with ep-ilepsy during 2015 and 2016 were collected and statistically analyzed in our hospital. Results: Without obvious difference in mean dose, the average plasma concentrations of oxcarbazepine in 3-6-year-old,6-10-year-old and 10-18-year-old children were significantly higher than those in less than 3-year-old children(P<0. 05). The mean dose and the average plasma concentrations of lamotrigine in children at different ages had no statistical significance(P>0. 05). The average plasma concentration of levetiracetam in less than 3-year-old children was significantly higher than that in the other children (P<0. 05). The effective rate of clinical treatment within dif-ferent plasma concentration ranges had statistical significance(P<0. 05). Conclusion: There are inter-individual differences in the plasma concentrations of antiepileptic drugs among the children with epilepsy at different ages. So the plasma concentration of antiepi-leptic drugs should be monitored regularly in order to ensure the safety and effectiveness of medication for children.